[7]
Society, E.A. Prevention of coronary heart disease: Scientific background and new clinical practice guidelines. Nutr. Metab. Cardiovasc. Dis., 1992, 2, 113-156.
[19]
Nawrocki, J.W.; Weiss, S.R.; Davidson, M.H.; Sprecher, D.L.; Schwartz, S.L.; Lupien, P.J.; Jones, P.H.; Haber, H.E.; Black, D.M. Perfusion, 1996, 9(3), 109-114.
[20]
Best, J.D.; Nicholson, G.C. Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes. Diabetes Nutr. Metab., 1996, 9, 74-80.
[21]
Ionica, F.E.; Pisoschi, C.; Negres, S.; Nikos, R.F.; Tarata, M.; Popescu, F. Atorvastain influence om glycemic control in patients with type 2 diabetes mellitus. Farmacia, 2010, 58(6), 728-734.
[26]
Chawla, P.A.; Pandey, S. Various analytical methods for analysis of atorvastatin: A review. J. Drug Deliv. Ther., 2019, 9(3-s), 885-899.
[29]
Althanoon, Z.; Faisal, I.M.; Ahmad, A.A.; Merkhan, M.M.; Merkhan, M.M. Pharmacological aspects of statins are relevant to their structural and physicochemical properties. Syst. Rev. Pharm, 2020, 11(7), 167-171.
[32]
Zaheer, Z.; Farooqui, M.N.; Mangle, A.A.; Nikalje, A.G. Stability-indicating high performance liquid chromatographic determination of atorvastatin calcium in pharmaceutical dosage form. Afr. J. Pharm. Pharmacol., 2008, 2(10), 204-210.
[37]
Harrington, P.J. Pharmaceutical process chemistry for synthesis: Rethinking the routes to scale-up; John Wiley & Sons, 2011.
[38]
Roth, B.D.; Arbor, A. Trans-6-[2-(3- or 4-carboxamidosubstituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis. U.S. Patent 4681893A, 1987.
[39]
Roth, B.D.; Arbor, A. [R-(R* R*)]-2-(4-fluorophenyl-β, δ- dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof. U.S. Patent 5273995, 1993.
[40]
Ye, J.; Liu, Y.; Li, C.L. Method for preparing atorvastatin calcium. C.N. Patent 101613312A, 2009.
[42]
Guntoori, B.R.; Che, D.; Wang, F.; Zhao, Y.; Murthy, K.S.K.; Horne, S.E. An improved preparation of atorvastatin. W.O. Patent 087723A1, 2005.
[43]
Guntoori, B.R.; Che, D.; Zhao, Y.; Murthy, K.S.K.; Horne, S.E. Preparation of atorvastatin. U.S. Patent 0203302A1, 2005.
[44]
Bell, E.L.; Finnigan, W.; France, S.P.; Green, A.P.; Hayes, M.A.; Hepworth, L.J.; Lovelock, S.L.; Niikura, H.; Osuna, S.; Romero, E.; Ryan, K.S.; Turner, N.J.; Flitsch, S.L. Biocatalysis. Nat. Rev. Methods Primers, 2021, 1(1)
[46]
Butler, D.E.; Dejone, R.L.; Nelson, J.D. Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4- hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4- phenyl-1H-pyrrole-3-carboxylic acid phenylamide. U.S. Patent 20020133026A1, 2002.
[49]
Butler, D.E. Process for trans-6-[2-(substituted-Pyrrol-1-yl) alkyl] pyran-2-one inhibitors of cholesterol synthesis. U.S. Patent 5298627, 1994.
[51]
Niddam, V.; Hadas, R.L.; Lifshitz, R.; Ishai, E. Hydrolysis of [R-(R* R*)]-2-(4-fluorophenyl-β, δ-dihydroxy-5-(1- methylethyl-3-phenyl-4-[(phenylamino) carbonyl]-1Hpyrrole- 1-heptanoic acid esters with calcium hydroxide. U.S. Patent 6528661, 2003.
[55]
Patel, D.J.; Kumar, R.; Dwivedi, S.P.D. Process for the preparation of atorvastatin calcium. W.O. Patent 096751A1, 2007.
[56]
Valerie, N.H.; Revital, L.L.; Rami, L.H. Process for preparing calcium salt forms of statins. U.S. Patent 6777552B2, 2004.
[57]
Sullivan, S.O.; Neill, J.O. Preparation of an atorvastatin intermediate. U.S. Patent 0221839A1, 2009.
[58]
Thottathil, J.K.; Pendri, Y.; Li, W.S.; Kronenthal, D.R. Process for the preparation of 1, 3-dioxane derivatives useful in the preparation of HMG-CoA reductase inhibitors. U.S. Patent 5278313, 1994.
[59]
Thottathil, J.K.; Pendri, Y.; Li, W.S.; Kronenthal, D.R. Process for the preparation of 1, 3-dioxane derivatives useful in the preparation of HMG-CoA reductase inhibitors. U.S. Patent 5457227, 1995.
[63]
Butler, D.E.; Deering, C.F.; Millar, A.; Nanninga, T.N.; Roth, B.D. Process for trans-6-[2-(substituted-pyrrol-1- yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis. U.S. Patent 5245047, 1993.
[65]
Thomas, T.; Poornaprajna, A.; Aswathanarayanappa, C.; Sridharan, M.; Ganesh, S. Process for stereoselective recution of β-ketoesters. U.S. Patent 7232920B2, 2007.
[66]
Bosch, R.L.; Mscabe, R.J.; Nanninga, T.N.; Stach, R.J. Process for the synthesis of 1, 3-diols. U.S. Patent 7232915B2, 2007.
[67]
Kooistra, J.H.M.H.; Zeegers, H.J.M.; Mink, D.; Mulders, J.M.C.A. Process for the preparation of 2-(6-substituted-1, 3-dioxane-4-yl) acetic acid derivatives. W.O. Patent 06266A1, 2002.
[68]
Mitsuda, M.; Miyazaki, M.; Inoue, K. Process for producing 6-caynomethyl-1, 3-dioxane-4-acetic acid derivatives. U.S. Patent 6344569B1, 2002.
[71]
Kizaki, N.; Yamada, Y.; Yasohara, Y.; Nishiyama, A.; Miyazaki, M.; Mitsuda, M.; Kondo, T.; Ueyama, N.; Inoue, K. Process for producing optically active 2-[6- (hydroxymethyl)-1, 3-dioxan-4-yl] acetic acid derivatives. U.S. Patent 0040634A1, 2003.
[78]
Davis, S.C.; Grate, J.H.; Gray, D.R.; Gruber, J.M.; Huisman, G.W.; Ma, S.K.; Newman, L.M.; Sheldon, R.; Wang, L.A. Enzymatic process for the production of 4-substituted 3-hydroxybutyric acid derivatives and vicinal cyano, hydroxy substituted carboxylic acid esters. W.O. Patent 018579A2, 2005.
[79]
Dicks, P. Green chemistry and associated metrics.Green Chemistry Metrics; Springer: Cham, 2015, pp. 1-15.
[80]
Giver, L.J.; Newman, L.S.; Mundorff, E.; Huisman, G.W.; Jenne, S.J.; Zhu, Z.; Behrouzian, B.; Grate, J.H.; Lalonde, J. Compositions and methods for produing stereoisomerically pure statins and synthetic intermediates therefor. U.S. Patent 0195465A1, 2011.
[82]
Mohammad, S.; Jitendra, S.; Yatendra, K.; Chander, A.R.; Krishna, R.V.; Anita, C. Substituted pyrrole derivatives. W.O. Patent 106299A2, 2004.
[83]
John, M.D.; William, W.J. Process and intermediate compounds useful in the preparation of statins, particularly atorvastatin. W.O. Patent 012246A, 2005.
[84]
Norman, B.D. Novel process for trans-6-[2-(Substituted- Pyrrol-1-Yl)Alkyl]Pyran-2-one inhibitors of cholesterol synthesis. W.O. Patent 1994020492, 1994.
[85]
Tararov, V.; Borner, A.; Konig, G.; Korostylev, A. Method for the production of statins. W.O. Patent 2006122644, 2006.
[87]
Sumitra, S.; Joy, M.; Sandhya, U.; Madhavan, S.; Ganesh, S. A process for the synthesis of atorvastatin form V and phenylboronates as intermediate conmpounds. W.O. Patent 057274A1, 2002.
[88]
Sumitra, S.; Joy, M.; Sandhya, U.; Madhavan, S.; Ganesh, S. Process for the synthesis of atorvastatin form V and phenylboronates as intermediate conmpounds. U.S. Patent 6867306B2, 2005.
[90]
Baisch, R.Ö. Pyrrole synthesis. W.O. Patent 2003044011, 2002.
[98]
Patel, V.; Baldha, R.; Patel, D. Simultaneous determination of atorvastatin calcium and ezetimib by ratio spectra derivative spectrophotometry and reverse phase-high performance liquid chromatography. Asian J. Chem., 2010, 22(4), 2507-2511.
[107]
Jemal, M.; Ouyang, Z.; Chen, B.C.; Teitz, D. Quantitation of Atorvastatin and its bio-transformation products in human serum by HPLC with electro spray tandem mass spectrometry. Rapid Communi. Mass Spectrom., 1999, 13, 1003-1015.
[111]
Shirkhedkar, A.; Surana, S. Simultaneous densitometric TLC analysis of atorvastatin calcium and fenofibrate in the bulk drug and in pharmaceutical formulations. JPC J. Planar Chromatog. Modern TLC, 2009, 22(5), 355-358.
[112]
Hiral, J.; Panchal, B.N.S.; Patel, N.J. Estimation of pitavastatin calcium in tablet dosage forms by column liquid chromatography and ultraviolet spectrophotometry. J. Planar Chromatog., 2009, 22(4), 265-271.
[113]
Hancu, G.; Tomegea, D.; Popescu, G.; Barabas-Hajdu, E. The use of capillary electrophoresis in the simultaneous determination of fixed-dose combination drugs for cardiovascular diseases. Trends Pharmacol. Sci., 2020, 6(3), 221-230.
[118]
Sharma, S.; Sharma, M.C. Determination of atorvastatin calcium and pioglitazone HCl in pharmaceutical formulations form by using atomic absorption spectrometry. Optoelectron. Adv. Mater. Rapid Commun., 2010, 4(8), 1196-1199.
[120]
Ayalon, A.; Levinger, M.; Roytblat, S.; Niddam, V.; Lifshitz, R.; Aronhime, J. Polymorphic form of atorvastatin calcium. U.S. Patent 7411075, 2008.
[121]
Briggs, C.; Jennings, R.; Wade, R.; Harasawa, K.; Ichikawa, S.; Minohara, K.; Nakagawa, S. Crystalline [R-(R*, R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethy l)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1- heptanoic acid hemi calcium salt (atorvastatin). U.S. Patent 005969156A, 1999.